AbbVie to assume full development and commercial control of cystic fibrosis research program

AbbVie ,a research-based global biopharmaceutical company, announced that it will assume full development and commercial responsibility for its collaboration with Galapagos to discover and develop new therapies to treat cystic fibrosis (CF)..

REGENXBIO announces positive interim phase I trial update for RGX-314

REGENXBIO Inc. a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, announced updated results...

Shionogi announces FDA approval of xofluza for the treatment of influenza

Shionogi announced recently that, after completing a Priority Review, the USA FDA has approved XOFLUZA for the treatment of acute, uncomplicated influenza in patients 12 years of age and older who have been...

Vetter further expands secondary packaging

Vetter is a leading solution provider of prefilled drug- delivery systems and a specialist for a wide range of packaging solutions. In addition to labelling, blister packing, cartoning as well as serialization, the company offers its customers further technically sophisticated...

Thermo Fisher Scientific annouces partnership with Symphogen

Thermo Fisher Scientific, the world leader in serving science, and Symphogen, a clinical-stage antibody oncology-focused company, have entered into a two- year collaborative partnership to deliver validated...

Idifarma strengthens Palobiofarma relationship with seventh project

SPANISH contract development and manufacturing organisation Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma. Under the terms of the agreement, Idifarma will handle...

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2018 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com